Literature DB >> 14558984

The J-curve in hypertension.

John Cruickshank1.   

Abstract

The J-curve debate has continued for 25 years. Dependency upon observational and retrospective studies has confused the issue; only the full publication of data from the prospective, randomized Hypertension Optimal Treatment (HOT) study has thrown genuine light on the problem. Many examples of the J-curve relationship between blood pressure and cardiovascular/noncardiovascular events are due to reverse causality, where underlying disease (eg, poor left ventricular function, poor general health, poorly compliant/stiff arteries) is the cause of both the low blood pressure and the increased risk of both cardiovascular and noncardiovascular events. The J-curve in patients with stiff arteries (wide pulse pressure) may be exacerbated by treatment. From the full publication of the HOT study database it is now reasonable to conclude that for nonischemic hypertensive subjects the therapeutic lowering of diastolic blood pressure (DBP) to the low 80s mm Hg is beneficial, but it is safe (though unproductive) to go lower. However, in the presence of coronary artery disease (limited coronary flow reserve) there is a J-curve relationship between treated DBP and myocardial infarction, but not for stroke. In such high-risk (for myocardial infarction) cases it would be prudent to avoid lowering DBP to below the low 80s mm Hg.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14558984     DOI: 10.1007/s11886-003-0105-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  85 in total

Review 1.  Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy.

Authors:  J M Cruickshank; J Lewis; V Moore; C Dodd
Journal:  J Hum Hypertens       Date:  1992-04       Impact factor: 3.012

2.  Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care.

Authors:  F J Klocke
Journal:  Circulation       Date:  1987-12       Impact factor: 29.690

3.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.

Authors:  S S Franklin; S A Khan; N D Wong; M G Larson; D Levy
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

4.  Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.

Authors:  G F Mitchell; L A Moyé; E Braunwald; J L Rouleau; V Bernstein; E M Geltman; G C Flaker; M A Pfeffer
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study.

Authors:  B M Psaty; C D Furberg; L H Kuller; M Cushman; P J Savage; D Levine; D H O'Leary; R N Bryan; M Anderson; T Lumley
Journal:  Arch Intern Med       Date:  2001-05-14

7.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

8.  The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program.

Authors:  S P Cooper; R J Hardy; D R Labarthe; C M Hawkins; E O Smith; M D Blaufox; C J Cooper; G Entwisle; M H Maxwell
Journal:  Am J Epidemiol       Date:  1988-02       Impact factor: 4.897

9.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

10.  Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study.

Authors:  Miranda T Schram; Pieter J Kostense; Robert A Van Dijk; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Robert J Heine; Coen D Stehouwer
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844

View more
  8 in total

Review 1.  The optimal blood pressure target for patients with coronary artery disease.

Authors:  Paolo Verdecchia; Fabio Angeli; Claudio Cavallini; Giovanni Mazzotta; Marta Garofoli; Paola Martire; Gianpaolo Reboldi
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

2.  Diastolic blood pressure levels and ischemic stroke incidence in older adults with white matter lesions.

Authors:  Shoshana Reshef; Linda Fried; Norman Beauchamp; Daniel Scharfstein; Daniel Reshef; Steven Goodman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-10-28       Impact factor: 6.053

3.  Clinical trials report. Hypertensive diabetic patients: INVESTing in the prevention of cardiovascular disease.

Authors:  Surender Arora; John Nicasio; Samy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

4.  Adrenal insufficiency after brain injury.

Authors:  Francis Bernard; Basil F Matta
Journal:  Intensive Care Med       Date:  2006-03-29       Impact factor: 17.440

Review 5.  J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?

Authors:  Nicolás Roberto Robles; Francesco Fici; Guido Grassi
Journal:  J Nephrol       Date:  2018-09-17       Impact factor: 3.902

Review 6.  Does a blood pressure J curve exist for patients with chronic kidney disease?

Authors:  Nicolás Roberto Robles; Roman Hernandez-Gallego; Francesco Fici; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-06-07       Impact factor: 3.738

Review 7.  Dispelling the myth of "aggressive" antihypertensive therapy.

Authors:  Elizabeth O Ofili
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

8.  How lifespan associated genes modulate aging changes: lessons from analysis of longitudinal data.

Authors:  Anatoliy I Yashin; Konstantin G Arbeev; Deqing Wu; Liubov S Arbeeva; Alexander Kulminski; Igor Akushevich; Irina Culminskaya; Eric Stallard; Svetlana V Ukraintseva
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.